Search

Displaying results 4051 - 4060 of 10000 in total
  1. Drug

    Telbivudine

    go.drugbank.com/drugs/DB01265
    ApprovedWithdrawn

    Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.

  2. Drug

    Filanesib

    go.drugbank.com/drugs/DB06040
    Investigational

    Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.

  3. Drug

    ICX-RHY

    go.drugbank.com/drugs/DB05716
    Experimental

    The drug was under investigation in clinical trials in the UK for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa. … ICX-RHY is an investigational therapy comprised of cultured allogeneic fibroblasts.

  4. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development.

  5. Drug

    Typhoid Vi polysaccharide vaccine

    go.drugbank.com/drugs/DB10803
    ApprovedInvestigational

    It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. … The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.

    Products: Typhim VI Solution for Injection in Multidose, Typhim Vi Injektionslösung in einer Fertigspritze
  6. Drug

    CPD 923

    go.drugbank.com/drugs/DB05856
    Experimental

    CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.

  7. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.

  8. Drug

    Bentoquatam

    go.drugbank.com/drugs/DB00516
    Approved

    Bentoquatam contains bentonite, a clay, and is only effective as long as the film is visible on the skin. … Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak.

  9. Drug

    SGN-15

    go.drugbank.com/drugs/DB05818
    Investigational

    SGN-15 is studied in the treatment of cancer. It combines a monoclonal antibody with the anticancer drug doxorubicin. … Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxorubicin is a type of anthracycline antitumor antibiotic.

  10. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia.